Targeting tumor-neural cell interactions to inhibit lung cancer brain metastasis
靶向肿瘤-神经细胞相互作用抑制肺癌脑转移
基本信息
- 批准号:10366021
- 负责人:
- 金额:$ 47.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-05 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAdenocarcinoma CellAnimal ModelAstrocytesBiological MarkersBlood - brain barrier anatomyBrainBrain NeoplasmsCancer EtiologyCancer PatientCell CommunicationCell NucleusCellsCessation of lifeClinical TrialsDataDiagnosisDifferentiated GeneDiseaseDrug usageExhibitsGenesGeneticGenetic TranscriptionGrowthHigh PrevalenceHumanImpaired cognitionImpairmentInflammatory ResponseKnowledgeLinkLung AdenocarcinomaLung NeoplasmsMalignant NeoplasmsMalignant neoplasm of lungMediatingMetastatic malignant neoplasm to brainMicrogliaMolecularMorbidity - disease rateNeoplasm MetastasisNervous system structureNeurodegenerative DisordersNeuroepithelial, Perineurial, and Schwann Cell NeoplasmNeurologic SymptomsNeuronal DifferentiationNeuronsNeurosciencesPathogenesisPathway interactionsPatientsPhosphotransferasesProcessProtein Tyrosine KinaseQuality of lifeReportingResearchResearch PersonnelRoleScientistSeizuresSignal TransductionSurvival RateTechnologyTestingTimeTranscriptTranscription CoactivatorTropismbrain dysfunctionbrain parenchymacancer typecell typedruggable targeteffective therapyexperienceexperimental studyinhibitorinnovationleukemialung cancer cellmimicrymortalitymouse modelneoplastic cellneurotoxicneurotoxicitynovelnovel markerpre-clinicalresponsetherapeutic targettranscription factortranscriptome sequencingtranscriptomicstreatment responsetumortumor microenvironmenttumor progression
项目摘要
Brain metastases account for decreased survival, increased morbidity, impaired cognition and poor quality of life
for patients with lung cancer. Effective therapies for the treatment of brain metastases are lacking due in part to
limited knowledge of the molecular mechanisms that regulate colonization of the brain parenchyma. Lung cancer
is the leading cause of cancer mortality in the U.S., with an overall five-year survival rate of ~16%. It is estimated
that ~ 234,030 new cases and ~ 154,050 deaths of lung cancer per year. Notably, ~40% of lung cancer patients
have metastases at the time of diagnosis, and exhibit the highest prevalence of brain metastasis (40-60 %)
among all cancer types. Current therapies to treat lung cancer brain metastases have proven ineffective due to
variable, transient and incomplete responses. We recently reported that allosteric inhibitors of the ABL kinases
cross the blood-brain barrier (BBB) and markedly impair the growth of brain metastases. Enhanced expression
of ABL and downstream target genes is linked to shortened survival of lung adenocarcinoma patients. We have
identified specific ABL-regulated transcription factors that mediate the brain metastatic potential of lung cancer
cells by regulating reciprocal crosstalk between brain metastases and neural cells. An unexpected role of this
ABL-regulated transcription network is that it promotes expression of neuronal signatures in brain metastatic
lung cancer cells. Acquisition of “neuronal mimicry” by lung tumors is a potential mechanistic adaptation to
achieve effective colonization and outgrowth in the brain by co-opting the function of neuronal cells, astrocytes
and microglia. In this regard, we found that inhibition of ABL kinases in lung cancer cells impairs deleterious
inflammatory responses of brain microglia cells. The overall hypothesis is that ABL-regulated transcription
networks promote brain metastasis, and that inhibition of ABL signaling enhances tumor cell vulnerabilities by
disrupting crosstalk between brain metastatic cells and resident neural cells in the brain tumor microenvironment.
To evaluate this hypothesis, we propose three specific aims: 1) Define the ABL-regulated transcription networks
that promote lung cancer brain metastasis and the mechanisms whereby inactivation of ABL kinases impairs
brain metastasis. 2) Evaluate whether inactivation of ABL kinases impairs metastatic colonization of the brain
parenchyma by disrupting tumor-neural cell crosstalk, while concomitantly blunting tumor-induced neurotoxicity.
3) Define the transcriptional landscape of lung cancer brain metastases and assess whether ABL-regulated
transcriptomic signatures identify lung cancer types that metastasize to the brain. To this end we will employ
state-of-the-art transcriptomic technologies to evaluate transcriptional changes, not only in brain metastasis, but
also among neural cell types in the surrounding brain parenchyma. Results from these experiments will reveal
the transcriptional landscapes of lung cancer brain metastases, critical to identify biomarkers and actionable
targets. Data generated will identity novel signaling networks that promote brain metastases and uncover novel
targets to treat this disease and decrease tumor-induced neurotoxicity.
脑转移导致生存率下降、发病率增加、认知受损和生活质量差
对于肺癌患者。缺乏治疗脑转移瘤的有效疗法,部分原因是
对调节脑实质定植的分子机制了解有限。肺癌
是美国癌症死亡的主要原因,总体五年生存率约为 16%。估计
每年约有 234,030 例新发肺癌病例和约 154,050 例肺癌死亡病例。值得注意的是,约 40% 的肺癌患者
诊断时已发生转移,且脑转移发生率最高 (40-60%)
在所有癌症类型中。目前治疗肺癌脑转移的疗法已被证明无效,原因是
可变的、瞬态的和不完整的响应。我们最近报道了 ABL 激酶的变构抑制剂
穿过血脑屏障(BBB)并显着损害脑转移瘤的生长。增强表达
ABL 和下游靶基因的缺失与肺腺癌患者的生存期缩短有关。我们有
鉴定出介导肺癌脑转移潜能的特定 ABL 调节转录因子
通过调节脑转移瘤和神经细胞之间的相互串扰来调节细胞。这个角色意想不到
ABL 调节的转录网络促进脑转移中神经元特征的表达
肺癌细胞。肺部肿瘤获得“神经元拟态”是一种潜在的机制适应
通过选择神经元细胞、星形胶质细胞的功能,在大脑中实现有效的定植和生长
和小胶质细胞。在这方面,我们发现抑制肺癌细胞中的 ABL 激酶会损害有害细胞。
脑小胶质细胞的炎症反应。总体假设是 ABL 调控的转录
网络促进脑转移,抑制 ABL 信号传导可通过以下方式增强肿瘤细胞的脆弱性:
破坏脑肿瘤微环境中脑转移细胞和常驻神经细胞之间的串扰。
为了评估这一假设,我们提出了三个具体目标:1)定义 ABL 调节的转录网络
促进肺癌脑转移以及 ABL 激酶失活损害的机制
脑转移。 2) 评估 ABL 激酶失活是否会损害大脑的转移定植
通过破坏肿瘤-神经细胞串扰来破坏实质,同时减弱肿瘤诱导的神经毒性。
3)定义肺癌脑转移的转录格局并评估ABL是否调控
转录组特征可识别转移至大脑的肺癌类型。为此,我们将聘请
最先进的转录组技术不仅可以评估脑转移中的转录变化,还可以评估转录变化
也存在于周围脑实质的神经细胞类型中。这些实验的结果将揭示
肺癌脑转移的转录景观,对于识别生物标志物和可操作至关重要
目标。生成的数据将识别促进脑转移的新信号网络并发现新的信号网络
目标是治疗这种疾病并减少肿瘤引起的神经毒性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ann Marie Pendergast其他文献
Ann Marie Pendergast的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ann Marie Pendergast', 18)}}的其他基金
Targeting tumor-neural cell interactions to inhibit lung cancer brain metastasis
靶向肿瘤-神经细胞相互作用抑制肺癌脑转移
- 批准号:
10164550 - 财政年份:2021
- 资助金额:
$ 47.98万 - 项目类别:
Targeting tumor-neural cell interactions to inhibit lung cancer brain metastasis
靶向肿瘤-神经细胞相互作用抑制肺癌脑转移
- 批准号:
10581652 - 财政年份:2021
- 资助金额:
$ 47.98万 - 项目类别:
Targeting ABL kinases to regulate epithelial cell plasticity and regeneration following injury
靶向 ABL 激酶调节损伤后上皮细胞可塑性和再生
- 批准号:
10666351 - 财政年份:2020
- 资助金额:
$ 47.98万 - 项目类别:
Targeting ABL kinases to regulate epithelial cell plasticity and regeneration following injury
靶向 ABL 激酶调节损伤后上皮细胞可塑性和再生
- 批准号:
10396637 - 财政年份:2020
- 资助金额:
$ 47.98万 - 项目类别:
Novel target for therapy refractory lung tumors
治疗难治性肺部肿瘤的新靶点
- 批准号:
9269186 - 财政年份:2015
- 资助金额:
$ 47.98万 - 项目类别:
Novel target for therapy refractory lung tumors
治疗难治性肺部肿瘤的新靶点
- 批准号:
9065535 - 财政年份:2015
- 资助金额:
$ 47.98万 - 项目类别:
Novel target for therapy refractory lung tumors
治疗难治性肺部肿瘤的新靶点
- 批准号:
8882940 - 财政年份:2015
- 资助金额:
$ 47.98万 - 项目类别:
Kinase Target of Diverse Cell Surface Receptors in Cancer Invasion and Metastasis
癌症侵袭和转移中多种细胞表面受体的激酶靶点
- 批准号:
8657899 - 财政年份:2011
- 资助金额:
$ 47.98万 - 项目类别:
Kinase Target of Diverse Cell Surface Receptors in Cancer Invasion and Metastasis
癌症侵袭和转移中多种细胞表面受体的激酶靶点
- 批准号:
8458615 - 财政年份:2011
- 资助金额:
$ 47.98万 - 项目类别:
Kinase Target of Diverse Cell Surface Receptors in Cancer Invasion and Metastasis
癌症侵袭和转移中多种细胞表面受体的激酶靶点
- 批准号:
8199099 - 财政年份:2011
- 资助金额:
$ 47.98万 - 项目类别:
相似海外基金
Assessing The Impact of Heparanase and NDST2 Expression on Non-Small Cell Lung Adenocarcinoma Cell Motility
评估乙酰肝素酶和 NDST2 表达对非小细胞肺腺癌细胞运动的影响
- 批准号:
449570 - 财政年份:2020
- 资助金额:
$ 47.98万 - 项目类别:
Studentship Programs
Analysis of cancer metastasis and invasion mechanism using a new lung adenocarcinoma cell line.
使用新的肺腺癌细胞系分析癌症转移和侵袭机制。
- 批准号:
16K10689 - 财政年份:2016
- 资助金额:
$ 47.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Acquisition strategy of tumor-specific markers using established micropapillary pattern pulmonary adenocarcinoma cell line
使用已建立的微乳头模式肺腺癌细胞系获取肿瘤特异性标志物的策略
- 批准号:
26460441 - 财政年份:2014
- 资助金额:
$ 47.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The antibetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
抗生素药物二甲双胍在体外和体内抑制食管腺癌细胞增殖。
- 批准号:
25860540 - 财政年份:2013
- 资助金额:
$ 47.98万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
The cell permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferations and can be used as the molecular targeting dru
细胞通透肽抑制胰腺导管腺癌细胞增殖,可作为分子靶向药物
- 批准号:
25461969 - 财政年份:2013
- 资助金额:
$ 47.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic Research for elucidation of chemo-resistance in mucinous adenocarcinoma cell.
阐明粘液腺癌细胞化疗耐药性的基础研究。
- 批准号:
22791532 - 财政年份:2010
- 资助金额:
$ 47.98万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
TAS::75 0849::TAS IN THIS PHASE I SBIR THE BREAST CANCER ADENOCARCINOMA CELL LI
TAS::75 0849::TAS 在这一阶段 I SBIR 乳腺癌腺癌细胞 LI
- 批准号:
8164743 - 财政年份:2010
- 资助金额:
$ 47.98万 - 项目类别:
Role of Endothelin-1 in osteoblastic bone metastasis produced by a human lung adenocarcinoma cell line
Endothelin-1 在人肺腺癌细胞系产生的成骨细胞骨转移中的作用
- 批准号:
19790127 - 财政年份:2007
- 资助金额:
$ 47.98万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
CONNEXIN 43 EXPRESSION IN ADENOCARCINOMA CELL LINE
连接蛋白 43 在腺癌细胞系中的表达
- 批准号:
6972483 - 财政年份:2004
- 资助金额:
$ 47.98万 - 项目类别:
The mechanisms of highly metastetic capasity in highly metastatic subpopulations of lung adenocarcinoma cell line and these clinical applications
肺腺癌细胞系高转移亚群的高转移能力机制及临床应用
- 批准号:
15590831 - 财政年份:2003
- 资助金额:
$ 47.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)